1. Pink Sheet
  2. >>Biosimilars & Generics
  3. >>Biosimilars

US FDA’s Yim Hints At Revisiting Biosimilar Suffix Naming Convention, Reassures On Immunogenicity

 
• By Dave Wallace

In an ‘ask me anything’ Q&A on Reddit, Sarah Yim, director of US FDA’s Office of Therapeutic Biologics and Biosimilars, offered some insights on the US biologics naming convention, biosimilar interchangeability, and the possibility of future competition on cell and gene therapies.

Reddit Ask Me Anything
Sarah Yim challenged Reddit users to "ask me anything" about biosimilars. • Source: Shutterstock

Sarah Yim, director of the US Food and Drug Administration's Office of Therapeutic Biologics and Biosimilars, suggested the long-bemoaned suffix in biosimilar generic names could be reconsidered during a Reddit "ask me anything" session.

Key Takeaways

  • The OTBB Director said the pros and cons of the suffix in the biosimilar naming convention will continue to be assessed.

Appearing in the “medicine” subreddit, described as “a virtual lounge for physicians and other medical professionals from around the world...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Biosimilars & Generics

US FTC Continues Effort To Eliminate Orange Book’s Improper Patent Listings

 
• By Urtė Fultinavičiūtė

In a somewhat surprising move, President Trump’s Federal Trade Commission is continuing a crusade to delist improper listings from the FDA’s Orange Book. Law firm Polsinelli’s chair Chad Landmon discussed the impact of the move on the generic drug industry.

Generic Drug Office’s Policy Staff Returning To US FDA

 
• By Derrick Gingery

The group had been laid off as part of the 1 April reduction-in-force, which led to missed guidance publication deadlines.

Aurobindo, MSN Fail To Beat US Nuplazid Patent Expiring In August 2038

 
• By Dean Rudge

Acadia’s Nuplazid for hallucinations and delusions associated with Parkinson’s disease psychosis appears safe from generic competition until well into the next decade, following a favorable infringement and validity decision by a US district court.